COPD Treatment

COPD Treatment

The COPD treatment market is expected to register a CAGR of approx. 5.3% over the period of 2023-2030. Chronic obstructive pulmonary disease (COPD) is a group of diseases that cause airway obstruction and breathing problems. These include emphysema and chronic bronchitis. The rising prevalence of COPD, primarily due to factors like smoking, air pollution, and ageing populations, is the driving factor for the market growth of the COPD treatment market. For Instance, according to the WHO, in 2023, Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). Furthermore, the COPD treatment market has witnessed advancements in therapies, medications, and devices that aim to manage symptoms, improve lung function, and enhance the quality of life for COPD patients. The availability of new treatment options encourages the growth of the market. For instance, in 2022, GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime.

• Based on the type, the market has been categorized into chronic bronchitis and emphysema. Among them, the chronic bronchitis segment is expected to grow at the highest CAGR in the market. Chronic bronchitis is a group of lung diseases that causes airflow blockages and breathing issues. It is widespread among smokers and rising at a rapid pace. The prevalence of chronic bronchitis is increasing worldwide, especially among the elderly. Chronic bronchitis is a progressive disease that gets worse over time and is usually diagnosed in people over the age of 40. Chronic bronchitis is expected to increase with the ageing population, driving the growth of the chronic bronchitis segment of the COPD treatment market.
• Based on the drug class, the market has been categorized into bronchodilators, corticosteroids, combination drugs, roflumilast (phosphodiesterase-4 inhibitor), and others. Among them, the combination drugs segment is expected to grow at a higher CAGR in the market. Combination therapy uses multiple drugs, such as bronchodilators and corticosteroids, to relieve symptoms of COPD and improve lung function. Combination therapy is gaining in popularity as it offers a more effective treatment of COPD symptoms than monotherapy using only one drug. In addition, some combination therapies are available in a single inhaler device, which improves patient adherence and makes treatment more convenient. For instance, this combination therapy, marketed by Novartis, combines a LAMA (glycopyrronium) and a LABA (indacaterol) in a single inhaler device. It is indicated for the long-term maintenance treatment of COPD.
• Based on the distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Among them, the retail pharmacies category is to witness higher adoption of COPD treatment during the forecast period. The prevalence of COPD is increasingly leading to an increase in patients requiring medications to manage their symptoms, and this drives the demand for COPD medications from retail pharmacies. In addition, the convenience of filling prescriptions close to home is a significant factor contributing to the growth of the retail pharmacies segment. Patients with COPD often require regular medication refills, and having a retail pharmacy nearby makes it easier to access the needed medications. Moreover, retail pharmacies increasingly offer personalized services such as medication counseling and education for patients with COPD. This helps patients understand their medication regimens and manage their symptoms more effectively.
• For a better understanding of the market adoption of enzymes, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. COPD treatments have gained increasing popularity in North America due to various factors. The North America COPD treatment market is expected to grow in the coming years, driven by the increasing prevalence of COPD and growing awareness of COPD among healthcare professionals and the general population, the increasing smoking cessation efforts and the rise in air pollution levels. For instance, according to the American Lung Association, in the United States, In 2020, 12.5 million people, or 5.0% of adults, reported a diagnosis of COPD (chronic obstructive pulmonary disease, chronic bronchitis, or emphysema.
• Some of the major players operating in GSK plc, Cipla Inc., Boehringer Ingelheim, Verona Pharma plc, Circassia Group PLC, Pfizer Inc, Sanofi, Almirall, S.A, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc. among others. Several M&A’s along with partnerships have been undertaken.